Metabolism of the dual FLT-3/Aurora kinase inhibitor CCT241736 in preclinical and human in vitro models: Implication for the choice of toxicology species

CCT241736 is a dual fms-like tyrosine kinase 3 (FLT3)/Aurora kinase inhibitor in development for the treatment of acute myeloid leukaemia. The successful development of any new drug relies on adequate safety testing including preclinical toxicology studies. Selection of an appropriate preclinical sp...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Eur J Pharm Sci
Egile Nagusiak: Wood, Francesca L., Shepherd, Sam, Hayes, Angela, Liu, Manjuan, Grira, Katia, Mok, Yi, Atrash, Butrus, Faisal, Amir, Bavetsias, Vassilios, Linardopoulos, Spiros, Blagg, Julian, Raynaud, Florence I.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier Science B.V 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6892276/
https://ncbi.nlm.nih.gov/pubmed/30953752
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejps.2019.04.004
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak